Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 18
- 13F valueReported value at the end of Q2 2026
- $185.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ACXP, Q2 2026
No superinvestor reported holding ACXP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Acurx Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Scodari Joseph CDirector | PPurchase | +24.6K | $1.02 | +$25.1K | +800.5%27.7K after | |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Scodari Joseph CDirector | PPurchase | +24.6K | $0.00 | $0 | –24.6K after | Derivative |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Sailer CarlDirector | PPurchase | +24.6K | $1.02 | +$25.1K | +21.9%137.2K after | |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Sailer CarlDirector | PPurchase | +24.6K | $0.00 | $0 | –24.6K after | Derivative |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Luci David PPresident and CEO | PPurchase | +49.3K | $1.02 | +$50.2K | +4.7%1.10M after | |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Luci David PPresident and CEO | PPurchase | +49.3K | $0.00 | $0 | –49.3K after | Derivative |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Donohue James J.Director | PPurchase | +9.85K | $1.02 | +$10.0K | +78.8%22.4K after | |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Donohue James J.Director | PPurchase | +9.85K | $0.00 | $0 | –9.85K after | Derivative |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Deluccia Robert JDirector, 10% Owner | PPurchase | +49.3K | $1.02 | +$50.2K | +5.1%1.01M after | |
| Jan 8, 2025 (view filing) | Jan 6 | 2 days | Deluccia Robert JDirector, 10% Owner | PPurchase | +49.3K | $0.00 | $0 | –49.3K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Acurx Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 31,099 | $48.2K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 26,411 | $40.9K | 0.00% | +1,592+6.4% | Added |
| Vanguard Fiduciary Trust Co | 16,205 | $25.1K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 15,727 | $24.4K | 0.00% | −38,915−71.2% | Reduced |
| Prospect Financial Services LLC | 13,785 | $21.4K | 0.01% | 00.0% | Unchanged |
| Morgan Stanley | 7,500 | $11.6K | 0.00% | +1,000+15.4% | Added |
| Tower Research Capital LLC (TRC) | 2,744 | $4.25K | 0.00% | +1,713+166.1% | Added |
| Wells Fargo & Company | 2,300 | $3.56K | 0.00% | 00.0% | Unchanged |
| Westside Investment Management, Inc. | 1,650 | $2.56K | 0.00% | 00.0% | Unchanged |
| NBC Securities, Inc. | 1,500 | $2.33K | 0.00% | 00.0% | Unchanged |